Asset
Nendocabtagene Onogedleucel
Allogene Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04093596 | phase1 | completed | 2019-09-23 | 2025-01-27 | Allogene Therapeutics | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) |
FDA applications (0)
This company has no applications containing this asset.